GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lixte Biotechnology Holdings Inc (NAS:LIXT) » Definitions » Cyclically Adjusted Book per Share

Lixte Biotechnology Holdings (Lixte Biotechnology Holdings) Cyclically Adjusted Book per Share : $-0.86 (As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Lixte Biotechnology Holdings Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Lixte Biotechnology Holdings's adjusted book value per share for the three months ended in Mar. 2024 was $-0.166. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $-0.86 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -13.60% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -102.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Lixte Biotechnology Holdings was -13.60% per year. The lowest was -205.50% per year. And the median was -92.20% per year.

As of today (2024-06-05), Lixte Biotechnology Holdings's current stock price is $2.4501. Lixte Biotechnology Holdings's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $-0.86. Lixte Biotechnology Holdings's Cyclically Adjusted PB Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Lixte Biotechnology Holdings was 128.57. The lowest was 2.95. And the median was 19.05.


Lixte Biotechnology Holdings Cyclically Adjusted Book per Share Historical Data

The historical data trend for Lixte Biotechnology Holdings's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lixte Biotechnology Holdings Cyclically Adjusted Book per Share Chart

Lixte Biotechnology Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.10 -0.58 -0.57 -0.71 -0.85

Lixte Biotechnology Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.77 -0.83 -0.85 -0.85 -0.86

Competitive Comparison of Lixte Biotechnology Holdings's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Lixte Biotechnology Holdings's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lixte Biotechnology Holdings's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lixte Biotechnology Holdings's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Lixte Biotechnology Holdings's Cyclically Adjusted PB Ratio falls into.



Lixte Biotechnology Holdings Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Lixte Biotechnology Holdings's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.166/131.7762*131.7762
=-0.166

Current CPI (Mar. 2024) = 131.7762.

Lixte Biotechnology Holdings Quarterly Data

Book Value per Share CPI Adj_Book
201406 1.286 100.560 1.685
201409 0.784 100.428 1.029
201412 0.351 99.070 0.467
201503 -0.424 99.621 -0.561
201506 -0.541 100.684 -0.708
201509 -1.184 100.392 -1.554
201512 -1.802 99.792 -2.380
201603 -3.093 100.470 -4.057
201606 -2.834 101.688 -3.673
201609 -3.461 101.861 -4.477
201612 -4.117 101.863 -5.326
201703 -3.278 102.862 -4.199
201706 -1.739 103.349 -2.217
201709 -2.177 104.136 -2.755
201712 -2.590 104.011 -3.281
201803 -2.982 105.290 -3.732
201806 -3.367 106.317 -4.173
201809 -3.632 106.507 -4.494
201812 0.560 105.998 0.696
201903 0.188 107.251 0.231
201906 -0.093 108.070 -0.113
201909 -0.666 108.329 -0.810
201912 -0.954 108.420 -1.160
202003 -1.297 108.902 -1.569
202006 -1.631 108.767 -1.976
202009 -2.111 109.815 -2.533
202012 1.219 109.897 1.462
202103 3.064 111.754 3.613
202106 2.464 114.631 2.833
202109 1.873 115.734 2.133
202112 0.938 117.630 1.051
202203 -0.020 121.301 -0.022
202206 2.398 125.017 2.528
202209 1.749 125.227 1.840
202212 1.000 125.222 1.052
202303 0.349 127.348 0.361
202306 -0.484 128.729 -0.495
202309 0.633 129.860 0.642
202312 0.220 129.419 0.224
202403 -0.166 131.776 -0.166

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Lixte Biotechnology Holdings  (NAS:LIXT) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Lixte Biotechnology Holdings was 128.57. The lowest was 2.95. And the median was 19.05.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Lixte Biotechnology Holdings Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Lixte Biotechnology Holdings's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Lixte Biotechnology Holdings (Lixte Biotechnology Holdings) Business Description

Traded in Other Exchanges
N/A
Address
680 East Colorado Boulevard, Suite 180, Pasadena, CA, USA, 91101
Lixte Biotechnology Holdings Inc is a drug discovery company that has a developed unique, proprietary, first-in-class protein phosphatase inhibitor, LB-100, as its lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard anti-cancer therapies, including cytotoxic drugs, radiation, and immune checkpoint blockers. The Company's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and x-ray and immune checkpoint blockers.
Executives
Rene Bernards director KONINGSVAREN 37, ABCOUDE P7 1391AD
Van Der Baan Bastiaan Jeroen director HOGEWEG 4-H, AMSTERDAM P7 1098CB
Eric Forman 10 percent owner 117 E. 29TH ST., APT. 5A, NEW YORK NY 10016
Regina Brown director 248 ROUTE 25A, NO. 2, EAST SETAUKET NY 11733
Glenn Krinsky 10 percent owner C/O SRKP 1, INC., 1900 AVENUE OF THE STARS, SUITE 310, LOS ANGELES CA 90067
Yun Yen director 1301 OAKLAWN ROAD, ARCADIA CA 91006
Robert Greenberg 10 percent owner SKECHERS USA INC, 228 MANHATTAN BEACH BLVD, MANHATTAN BEACH CA 90266
Gil Schwartzberg 10 percent owner 269 S. BEVERLY DR., #1315, BEVERLY HILLS CA 90212
Philip F Palmedo director 1801 CENTURY PARK EAST #1600, LOS ANGELES CA 90067
John S Kovach director, 10 percent owner, officer: Pres., CFO & Secty 1801 CENTURY PARK EAST #1600, LOS ANGELES CA 90067
Stephen J. Forman director 248 ROUTE 25A, NO. 2, EAST SETAUKET NY 11733
Hung Tak Ho 10 percent owner MAYFAIR BY THE SEA II, TOWER T8, 1/F, UNIT A, 21 FO CHUN ROAD, PAK SHEK KOK, TAIPO K3 00000
Robert N Weingarten officer: Vice President and CFO 5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367
James Miser officer: Chief Medical Officer 680 E COLORADO BLVD., SUITE 180, PASADENA CA 91101
Jane Merrill Riggs 10 percent owner 4852 SAINT ANDRES AVENUE, LA VERNE CA 91750

Lixte Biotechnology Holdings (Lixte Biotechnology Holdings) Headlines

From GuruFocus